Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now? in Expert opinion on biological therapy / Expert Opin Biol Ther. 2025 Mar 28. doi: 10.1080/14712598.2025.2484844.
2025
ASL Città di Torino
ASL Città di Torino
Tipo pubblicazione
Editorial
Autori/Collaboratori (9)Vedi tutti...
Radin M
Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.
Barinotti A
Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.
Galarza D
Department of Rheumatology, Hospital del Mar Barcelona, Barcelona, Spain.
et alii...
Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.
Barinotti A
Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.
Galarza D
Department of Rheumatology, Hospital del Mar Barcelona, Barcelona, Spain.
et alii...
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.
PMID : 40151064
DOI : 10.1080/14712598.2025.2484844
Keywords
APS; Belimumab; antiphospholipid; thrombocytopenia;